Clinical Trial

Development of a Pan-Cancer Screening Model Based on Blood Biomarkers

Study acronym: PanCanBlood
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to develop a pan-cancer screening model using routine blood biomarkers (including complete blood count, biochemical tests, coagulation panel, and tumor markers). The study is retrospective, collecting data from approximately 10,000,000 cancer patients diagnosed at multiple centers in China between January 2006 and September 2025. All patients have confirmed pathological diagnosis and complete blood test records. A Mixture of Experts (MoE) machine learning model will be built to predict the presence of various cancers (e.g., gastric, colorectal, liver, lung, ovarian cancer). The goal is to establish a low-cost, non-invasive screening tool suitable for large-scale population screening.
Trial Details
NCT Number NCT07554157
Lead Sponsor Zhejiang Cancer Hospital
Conditions Neoplasms
Enrollment 10,000,000 participants
Start Date 2025-10-22
Primary Completion 2027-07-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-28